You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMeprobamate
Accession NumberDB00371  (APRD01095)
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionA carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of anxiety disorders, and also for the short-term management of insomnia but has largely been superseded by the benzodiazepines. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603) Meprobamate is a controlled substance in the U.S.
Structure
Thumb
Synonyms
Equanil
Meprobamat
Meprobamato
Meprobamatum
Meprobamic acid
Miltown
External Identifiers
  • DEA No. 2820
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Equanil Tablets 400mgtablet400 mgoralWyeth Ayerst Canada Inc.1994-12-312000-03-07Canada
Meditran 400mgtablet400 mgoralMedic Laboratory LtÉe1959-12-311996-09-09Canada
Meprobamate Tab 400mgtablet400 mgoralPro Doc Limitee1959-12-312001-10-15Canada
Meprobamate Tab 400mgtablet400 mgoralDuchesnay Inc1978-12-312001-10-15Canada
Novo-mepro 200mgtablet200 mgoralNovopharm Limited1967-12-312005-08-10Canada
Novo-mepro 400mgtablet400 mgoralNovopharm Limited1967-12-312005-08-10Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Meprobamate Tab 400mgtablet400 mgoralApotex Inc1975-12-312001-10-09Canada
Meprobamatetablet400 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2011-05-23Not applicableUs
Meprobamatetablet200 mg/1oralAvera Mc Kennan Hospital2015-11-03Not applicableUs
Meprobamatetablet400 mg/1oralWatson Laboratories, Inc.1973-05-03Not applicableUs
Meprobamatetablet400 mg/1oralDr.Reddy's Laboratories Limited2008-01-03Not applicableUs
Meprobamatetablet200 mg/1oralAlembic Pharmaceuticals Limited2013-07-23Not applicableUs
Meprobamatetablet200 mg/1oralTaro Pharmaceutical Industries Ltd.2011-05-23Not applicableUs
Meprobamatetablet200 mg/1oralWatson Laboratories, Inc.1973-04-23Not applicableUs
Meprobamatetablet200 mg/1oralAlembic Pharmaceuticals Inc.2015-12-01Not applicableUs
Meprobamatetablet400 mg/1oralAlembic Pharmaceuticals Limited2013-07-23Not applicableUs
Meprobamatetablet400 mg/1oralTaro Pharmaceutical Industries Ltd.2011-05-23Not applicableUs
Meprobamatetablet200 mg/1oralHeritage Pharmaceuticals Inc.2009-05-01Not applicableUs
Meprobamatetablet400 mg/1oralAlembic Pharmaceuticals Inc.2015-12-01Not applicableUs
Meprobamatetablet200 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2011-05-23Not applicableUs
Meprobamatetablet200 mg/1oralDr.Reddy's Laboratories Limited2008-01-03Not applicableUs
Meprobamatetablet400 mg/1oralHeritage Pharmaceuticals Inc.2009-05-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EquanilWyeth
MeprospanNot Available
MiltownWallace Laboratories
Brand mixtures
NameLabellerIngredients
282 Mep TabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
Equagesic TabletsWyeth Ayerst Canada Inc.
SaltsNot Available
Categories
UNII9I7LNY769Q
CAS number57-53-4
WeightAverage: 218.2502
Monoisotopic: 218.126657074
Chemical FormulaC9H18N2O4
InChI KeyInChIKey=NPPQSCRMBWNHMW-UHFFFAOYSA-N
InChI
InChI=1S/C9H18N2O4/c1-3-4-9(2,5-14-7(10)12)6-15-8(11)13/h3-6H2,1-2H3,(H2,10,12)(H2,11,13)
IUPAC Name
2-[(carbamoyloxy)methyl]-2-methylpentyl carbamate
SMILES
CCCC(C)(COC(N)=O)COC(N)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as organooxygen compounds. These are organic compounds containing a bond between a carbon atom and an oxygen atom.
KingdomOrganic compounds
Super ClassOrganooxygen compounds
ClassNot Available
Sub ClassNot Available
Direct ParentOrganooxygen compounds
Alternative Parents
Substituents
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the management of anxiety disorders or for the short-term relief of the symptoms of anxiety.
PharmacodynamicsMeprobamate is an anxiolytic drug. It was the best selling minor tranquilizer for a time but has largely been replaced by benzodiazepines. Meprobamate has most of the pharmacological effects and dangers of the barbiturates (though it was marketed as being safer). However, it is less sedating at effective doses. It is reported to have some anticonvulsant properties against absence seizures, but can exacerbate generalized tonic-clonic seizures. It has also been used as a hypnotic (sleeping pill). However, its is currently only licensed as an anxiolytic and it is a third or fourth-order choice.
Mechanism of actionMeprobamate's mechanism of action is not known. It has been shown in animal studies to have effects at multiple sites in the central nervous system, including the thalamus and limbic system. Meprobamate binds to GABAA receptors which interrupt neuronal communication in the reticular formation and spinal cord, causing sedation and altered perception of pain.
Related Articles
AbsorptionWell absorbed from the gastrointestinal tract.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half lifePlasma half-life is about 10 hours.
ClearanceNot Available
ToxicitySymptoms of overdose include coma, drowsiness, loss of muscle control, severely impaired breathing, shock, sluggishness, and unresponsiveness. Death has been reported with ingestion of as little as 12 g meprobamate and survival with as much as 40 g.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Capecitabine Metabolism PathwayDrug metabolismSMP00607
Capecitabine Action PathwayDrug actionSMP00469
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9534
Blood Brain Barrier+0.9864
Caco-2 permeable-0.5731
P-glycoprotein substrateNon-substrate0.5282
P-glycoprotein inhibitor INon-inhibitor0.8781
P-glycoprotein inhibitor IINon-inhibitor0.9033
Renal organic cation transporterNon-inhibitor0.945
CYP450 2C9 substrateNon-substrate0.9108
CYP450 2D6 substrateNon-substrate0.8961
CYP450 3A4 substrateNon-substrate0.7032
CYP450 1A2 substrateNon-inhibitor0.8381
CYP450 2C9 inhibitorNon-inhibitor0.8799
CYP450 2D6 inhibitorNon-inhibitor0.8764
CYP450 2C19 inhibitorNon-inhibitor0.8754
CYP450 3A4 inhibitorNon-inhibitor0.8735
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8914
Ames testNon AMES toxic0.8706
CarcinogenicityNon-carcinogens0.7304
BiodegradationNot ready biodegradable0.965
Rat acute toxicity2.4075 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9943
hERG inhibition (predictor II)Non-inhibitor0.9322
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Glaxosmithkline llc
  • Medpointe pharmaceuticals medpointe healthcare inc
  • Wyeth ayerst laboratories
  • Ferndale laboratories inc
  • Alra laboratories inc
  • Teva pharmaceuticals usa inc
  • Alembic ltd
  • Barr laboratories inc
  • Elkins sinn div ah robins co inc
  • Heather drug co inc
  • Impax laboratories inc
  • Invagen pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Ivc industries inc dba inverness medical nutritionals group
  • Lannett co inc
  • Lederle laboratories div american cyanamid co
  • Km lee laboratories inc
  • Mallard inc
  • Mk laboratories inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Nexgen pharma inc
  • Parke davis div warner lambert co
  • L perrigo co
  • Pharmavite pharmaceuticals
  • Purepac pharmaceutical co
  • Private formulations inc
  • Roxane laboratories inc
  • Sandoz inc
  • Scherer laboratories inc
  • Solvay pharmaceuticals
  • Stanlabs pharmaceutical co sub simpak corp
  • Tablicaps inc
  • Usl pharma inc
  • Valeant pharmaceuticals international
  • Vangard laboratories inc div midway medical co
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Whiteworth towne paulsen inc
  • Halsey drug co inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral
Tabletoral400 mg
Tabletoral200 mg/1
Tabletoral400 mg/1
Tabletoral200 mg
Prices
Unit descriptionCostUnit
Mepron 750 mg/5ml Suspension5.41USD ml
Mepron 750 mg/5 ml suspension4.95USD ml
Meprobamate 200 mg tablet1.42USD tablet
Meprobamate 400 mg tablet0.84USD tablet
Meprozine 50-25 mg capsule0.78USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1336266 No1995-07-112012-07-11Canada
CA2152615 No2001-10-162013-12-23Canada
US4981874 No1992-08-152009-08-15Us
US6649659 No1997-01-102017-01-10Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point105 °CPhysProp
water solubility4700 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.70HANSCH,C ET AL. (1995)
logS-1.67ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility2.47 mg/mLALOGPS
logP1.06ALOGPS
logP0.93ChemAxon
logS-1.9ALOGPS
pKa (Strongest Acidic)15.17ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area104.64 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity53.04 m3·mol-1ChemAxon
Polarizability22.65 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (10.1 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN05BC51N05CX01N05BC01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (52.6 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Meprobamate is combined with 7-Nitroindazole.
AbirateroneThe metabolism of Meprobamate can be decreased when combined with Abiraterone.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Meprobamate.
AcepromazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Aceprometazine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Meprobamate.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Meprobamate.
adipiplonThe risk or severity of adverse effects can be increased when Meprobamate is combined with adipiplon.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Meprobamate.
AgomelatineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Agomelatine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Meprobamate.
AlfaxaloneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Meprobamate is combined with Alfentanil.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Meprobamate.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Alprazolam.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Meprobamate.
AmisulprideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Amisulpride.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Meprobamate.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Meprobamate.
AmobarbitalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Amperozide.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Meprobamate.
AripiprazoleThe risk or severity of adverse effects can be increased when Meprobamate is combined with Aripiprazole.
ArmodafinilThe metabolism of Meprobamate can be decreased when combined with Armodafinil.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Meprobamate.
ArticaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Asenapine.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Meprobamate.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Meprobamate.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Meprobamate.
AzaperoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Azaperone.
AzelastineMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Meprobamate.
BaclofenThe risk or severity of adverse effects can be increased when Meprobamate is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Barbital.
BenzocaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Meprobamate is combined with Benzyl alcohol.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Meprobamate.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Meprobamate.
BortezomibThe metabolism of Meprobamate can be decreased when combined with Bortezomib.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Meprobamate.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Meprobamate.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Meprobamate is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.
BrimonidineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Bromazepam.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Meprobamate.
BrompheniramineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Meprobamate.
BuprenorphineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Meprobamate is combined with Buspirone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Meprobamate.
ButacaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Meprobamate is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Butorphanol.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Meprobamate.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Meprobamate.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Meprobamate.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Meprobamate.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Meprobamate.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Meprobamate.
CarbinoxamineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Meprobamate is combined with Carfentanil.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Meprobamate.
CarisoprodolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Carisoprodol.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Meprobamate.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Meprobamate.
CetirizineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chloral hydrate.
ChloramphenicolThe metabolism of Meprobamate can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chlordiazepoxide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chloroprocaine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chlorphenamine.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Meprobamate.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Meprobamate.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Meprobamate can be decreased when combined with Cholecalciferol.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Meprobamate.
CimetidineThe metabolism of Meprobamate can be decreased when combined with Cimetidine.
CinchocaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cinchocaine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Meprobamate.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Meprobamate.
CitalopramThe risk or severity of adverse effects can be increased when Meprobamate is combined with Citalopram.
CitalopramThe metabolism of Meprobamate can be decreased when combined with Citalopram.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Meprobamate.
ClemastineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Meprobamate is combined with Clidinium.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Meprobamate.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Meprobamate.
clomethiazoleThe risk or severity of adverse effects can be increased when Meprobamate is combined with clomethiazole.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Meprobamate.
ClomipramineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Clonazepam.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Meprobamate.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Meprobamate.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Meprobamate.
ClorazepateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Clorazepate.
ClotrimazoleThe metabolism of Meprobamate can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Meprobamate.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Meprobamate.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Meprobamate.
CocaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Meprobamate.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Meprobamate.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Meprobamate.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Meprobamate.
CyclizineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cyclobenzaprine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Meprobamate.
CyproheptadineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Meprobamate can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Meprobamate.
DabrafenibThe serum concentration of Meprobamate can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Meprobamate.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Meprobamate.
DantroleneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dantrolene.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Meprobamate.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Meprobamate.
DapoxetineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dapoxetine.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Meprobamate.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Meprobamate.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Meprobamate.
DelavirdineThe metabolism of Meprobamate can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Meprobamate is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Detomidine.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Meprobamate.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dexmedetomidine.
DextromoramideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dezocine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Meprobamate.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Meprobamate.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Meprobamate.
DifenoxinThe risk or severity of adverse effects can be increased when Meprobamate is combined with Difenoxin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Meprobamate.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Meprobamate.
DihydrocodeineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dihydromorphine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Meprobamate.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Meprobamate.
DimenhydrinateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Diphenoxylate.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Meprobamate.
DisulfiramThe metabolism of Meprobamate can be decreased when combined with Disulfiram.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Meprobamate.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Meprobamate.
DoramectinThe risk or severity of adverse effects can be increased when Meprobamate is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Meprobamate is combined with Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Meprobamate.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.
DoxylamineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Meprobamate is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.
DroperidolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dyclonine.
EcgonineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Meprobamate is combined with ECGONINE METHYL ESTER.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Meprobamate.
EfavirenzThe risk or severity of adverse effects can be increased when Meprobamate is combined with Efavirenz.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Meprobamate.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Meprobamate.
EntacaponeThe risk or severity of adverse effects can be increased when Meprobamate is combined with Entacapone.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Meprobamate.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Meprobamate.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Meprobamate.
EscitalopramThe risk or severity of adverse effects can be increased when Meprobamate is combined with Escitalopram.
Eslicarbazepine acetateThe metabolism of Meprobamate can be decreased when combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Meprobamate can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Estazolam.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Meprobamate.
EstriolThe serum concentration of Estriol can be increased when it is combined with Meprobamate.
EstroneThe serum concentration of Estrone can be increased when it is combined with Meprobamate.
EszopicloneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Eszopiclone.
EthanolMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Meprobamate.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Meprobamate.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Meprobamate.
EthosuximideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Meprobamate.
EtoperidoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Etoperidone.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Meprobamate.
EtorphineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Etorphine.
EtravirineThe metabolism of Meprobamate can be decreased when combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Meprobamate.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Meprobamate.
EzogabineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fentanyl.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Meprobamate.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Meprobamate.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Meprobamate.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Meprobamate.
FlibanserinThe risk or severity of adverse effects can be increased when Meprobamate is combined with Flibanserin.
FluconazoleThe metabolism of Meprobamate can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fluoxetine.
FluoxetineThe metabolism of Meprobamate can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Meprobamate.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fospropofol.
GabapentinThe risk or severity of adverse effects can be increased when Meprobamate is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Meprobamate is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Meprobamate is combined with Gamma Hydroxybutyric Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Meprobamate.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Meprobamate.
GemfibrozilThe metabolism of Meprobamate can be decreased when combined with Gemfibrozil.
GlutethimideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Glutethimide.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Meprobamate.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Meprobamate.
GuanfacineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Halazepam.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Meprobamate.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Meprobamate.
HalothaneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Meprobamate is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Hexobarbital.
HydrocodoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Hydrocodone.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Meprobamate.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Meprobamate.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.
HydroxyzineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Hydroxyzine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Meprobamate.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Meprobamate.
IloperidoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Iloperidone.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Meprobamate.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Meprobamate.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Meprobamate.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Meprobamate.
IndalpineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Indalpine.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Meprobamate.
IndinavirThe metabolism of Meprobamate can be decreased when combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Meprobamate.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Meprobamate.
IsofluraneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Isoflurane.
IsoniazidThe metabolism of Meprobamate can be decreased when combined with Isoniazid.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Meprobamate.
KetamineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Meprobamate.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Meprobamate.
KetobemidoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ketobemidone.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Meprobamate.
KetoconazoleThe metabolism of Meprobamate can be decreased when combined with Ketoconazole.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Meprobamate.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Meprobamate.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Meprobamate.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Meprobamate.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Meprobamate.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Meprobamate.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Meprobamate.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Meprobamate.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Meprobamate.
LevobupivacaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Meprobamate is combined with Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Meprobamate.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Meprobamate is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Levorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Meprobamate.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Meprobamate.
LithiumThe risk or severity of adverse effects can be increased when Meprobamate is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Meprobamate is combined with Lofentanil.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Meprobamate.
LopinavirThe metabolism of Meprobamate can be increased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Meprobamate.
LosartanThe serum concentration of Losartan can be increased when it is combined with Meprobamate.
LoxapineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Loxapine.
Lu AA21004The risk or severity of adverse effects can be increased when Meprobamate is combined with Lu AA21004.
LuliconazoleThe serum concentration of Meprobamate can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Meprobamate can be decreased when it is combined with Lumacaftor.
LurasidoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Magnesium Sulfate.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Meprobamate.
MaprotilineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Medetomidine.
MefloquineThe therapeutic efficacy of Meprobamate can be decreased when used in combination with Mefloquine.
MelatoninThe risk or severity of adverse effects can be increased when Meprobamate is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Mepivacaine.
MesoridazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Meprobamate.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methohexital.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Meprobamate.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methylphenobarbital.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Meprobamate.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Meprobamate.
MetyrosineMeprobamate may increase the sedative activities of Metyrosine.
MianserinThe therapeutic efficacy of Meprobamate can be decreased when used in combination with Mianserin.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Meprobamate.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Meprobamate.
MilnacipranThe risk or severity of adverse effects can be increased when Meprobamate is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Meprobamate.
MirtazapineMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Meprobamate.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Meprobamate.
MoclobemideThe metabolism of Meprobamate can be decreased when combined with Moclobemide.
ModafinilThe metabolism of Meprobamate can be decreased when combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Molindone.
MorphineThe serum concentration of Morphine can be increased when it is combined with Meprobamate.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Meprobamate.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Meprobamate.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.
NabiloneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Nabilone.
NadololThe serum concentration of Nadolol can be increased when it is combined with Meprobamate.
NalbuphineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Nalbuphine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Meprobamate.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Meprobamate.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Meprobamate.
NelfinavirThe metabolism of Meprobamate can be decreased when combined with Nelfinavir.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Meprobamate.
NicardipineThe metabolism of Meprobamate can be decreased when combined with Nicardipine.
NicotineThe metabolism of Meprobamate can be decreased when combined with Nicotine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Meprobamate.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Meprobamate.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Meprobamate.
NitrazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Nitrous oxide.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Meprobamate.
NormethadoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Olopatadine.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Meprobamate.
OmeprazoleThe metabolism of Meprobamate can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Meprobamate is combined with Opium.
OrlistatThe serum concentration of Meprobamate can be decreased when it is combined with Orlistat.
OrphenadrineMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Meprobamate.
OsanetantThe risk or severity of adverse effects can be increased when Meprobamate is combined with Osanetant.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Meprobamate.
OxazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Meprobamate is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Oxymorphone.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Meprobamate.
PaliperidoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Paliperidone.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Meprobamate.
PantoprazoleThe metabolism of Meprobamate can be decreased when combined with Pantoprazole.
ParaldehydeMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Meprobamate.
ParoxetineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Meprobamate.
PentazocineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Meprobamate.
PerampanelThe risk or severity of adverse effects can be increased when Meprobamate is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Meprobamate is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pethidine.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Meprobamate.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Meprobamate.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Phenoxyethanol.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Meprobamate.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Meprobamate.
PimozideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pipotiazine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Meprobamate.
PizotifenThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pizotifen.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Meprobamate.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Meprobamate.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Meprobamate.
PramipexoleMeprobamate may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pramocaine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Meprobamate.
PrazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Prazepam.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Meprobamate.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Meprobamate.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Meprobamate.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Meprobamate.
PrilocaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Prilocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Procaine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Prochlorperazine.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Meprobamate.
PromazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Propoxycaine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Meprobamate.
ProtriptylineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Meprobamate.
PSD502The risk or severity of adverse effects can be increased when Meprobamate is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Quazepam.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Meprobamate.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Meprobamate.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Meprobamate.
QuinineThe serum concentration of Quinine can be increased when it is combined with Meprobamate.
RamelteonThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ramelteon.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Meprobamate.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Meprobamate.
RemifentanilThe risk or severity of adverse effects can be increased when Meprobamate is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Remoxipride.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Meprobamate.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Meprobamate.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Meprobamate.
RifampicinThe metabolism of Meprobamate can be increased when combined with Rifampicin.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Meprobamate.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Meprobamate.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Meprobamate.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Meprobamate.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Meprobamate.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Meprobamate.
RomifidineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Romifidine.
RopiniroleMeprobamate may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Meprobamate.
RotigotineMeprobamate may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Meprobamate.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Meprobamate is combined with S-Ethylisothiourea.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Meprobamate.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Meprobamate.
ScopolamineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Secobarbital.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Meprobamate.
SertindoleThe risk or severity of adverse effects can be increased when Meprobamate is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Sertraline.
SertralineThe metabolism of Meprobamate can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Sevoflurane.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Meprobamate.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Meprobamate.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Meprobamate.
Sodium oxybateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Sodium oxybate.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Meprobamate.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Meprobamate.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Meprobamate.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Meprobamate.
StiripentolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Meprobamate is combined with Sufentanil.
SulpirideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Sulpiride.
SuvorexantThe risk or severity of adverse effects can be increased when Meprobamate is combined with Suvorexant.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Meprobamate.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Meprobamate.
TapentadolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Meprobamate.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Meprobamate.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Meprobamate.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Meprobamate.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Meprobamate.
TetrabenazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tetrodotoxin.
ThalidomideMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Meprobamate.
ThiamylalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Thiopental.
ThioridazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tiagabine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Meprobamate.
TiclopidineThe metabolism of Meprobamate can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tiletamine.
TimololThe serum concentration of Timolol can be increased when it is combined with Meprobamate.
TizanidineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tolcapone.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Meprobamate.
TopiramateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Meprobamate.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Meprobamate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Meprobamate.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Meprobamate.
TrazodoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Triflupromazine.
TrimipramineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Triprolidine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Meprobamate.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Meprobamate.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Meprobamate.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Meprobamate.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Meprobamate.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Meprobamate.
VigabatrinThe risk or severity of adverse effects can be increased when Meprobamate is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Vilazodone.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Meprobamate.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Meprobamate.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Meprobamate.
VoriconazoleThe metabolism of Meprobamate can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Xylazine.
YohimbineThe therapeutic efficacy of Meprobamate can be decreased when used in combination with Yohimbine.
ZaleplonThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Meprobamate.
ZimelidineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Meprobamate.
ZolazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zolpidem.
ZonisamideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zuclopenthixol.
Food Interactions
  • Take without regard to meals. Avoid alcohol.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [PubMed:9067327 ]
  2. Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [PubMed:9067327 ]
  2. Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [PubMed:9067327 ]
  2. Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA4
Uniprot ID:
P48169
Molecular Weight:
61622.645 Da
References
  1. Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [PubMed:9067327 ]
  2. Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [PubMed:9067327 ]
  2. Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA6
Uniprot ID:
Q16445
Molecular Weight:
51023.69 Da
References
  1. Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [PubMed:9067327 ]
  2. Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. ChEMBL Compound Report Card [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23